Reported Earnings • 14h
Second quarter 2026 earnings released: kr0.03 loss per share (vs kr0.57 loss in 2Q 2025) Second quarter 2026 results: kr0.03 loss per share (improved from kr0.57 loss in 2Q 2025). Revenue: kr83.0m (up 31% from 2Q 2025). Net loss: kr880.0k (loss narrowed 95% from 2Q 2025). Revenue is forecast to grow 8.9% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 31% per year, which means it has not declined as severely as earnings. Duyuru • Feb 27
Mentice AB (publ) Announces Board Changes Mentice AB (publ) at its EGM held on February 26, 2026, announced that Göran Malmberg, previously CEO of the Company, was elected, for the period until the next annual shareholders’ meeting, as a new board member in the Company. Former board members David J. Ballard, Eola Änggård Runsten and Magnus Nilsson stepped down from the board. Göran Malmberg served as a board member in 2007 before assuming the role of CEO in January 2008, a position he held until December 31, 2024, when Frans Venker assumed the role as new CEO. Since 2025, Göran Malmberg serves as an advisor to the Company and its owners, and following the recent change of ownership, he now in addition assumes the role of board member. Duyuru • Feb 12
Mentice AB (publ) to Report Fiscal Year 2025 Final Results on Apr 23, 2026 Mentice AB (publ) announced that they will report fiscal year 2025 final results at 9:00 AM, Central European Standard Time on Apr 23, 2026 Duyuru • Oct 24
Mentice AB (publ), Annual General Meeting, May 26, 2026 Mentice AB (publ), Annual General Meeting, May 26, 2026. Location: gothenburg Sweden Duyuru • Jul 24
Mentice AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 31.961063 million. Mentice AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 31.961063 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 2,556,885
Price\Range: SEK 12.5
Transaction Features: Rights Offering Duyuru • Jul 11
Mentice AB (publ) Announces Consolidation of Physical Simulation Operations to Strengthen Long-Term Efficiency and Global Service Delivery Mentice AB (publ) announced the decision to consolidate its research and development (R&D) and manufacturing operations for its entire physical simulation portfolio to its new facility in Denver, Colorado, USA. Duyuru • Nov 29
Mentice AB (publ) Announces the Appointment of Frans Venker as New Chief Executive Officer, Effective January 1, 2025 Mentice AB (publ) announced the appointment of Frans Venker as its new Chief Executive Officer, effective January 1, 2025. Frans Venker succeeds Göran Malmberg, who has served the company for 17 years and will remain in an advisory role. Göran Malmberg’s retirement as CEO was previously announced in May 2024. With over 25 years of experience in the industry addressing the same or related medical needs and therapies as Mentice, Venker brings a wealth of expertise and a proven track record in driving innovation, operational excellence, and sustainable growth. Most recently, he led the Business Unit for Computed Tomography and Advanced Molecular Imaging at Philips based in the USA. Before this role, he was the Business Leader of image-guided Therapy for Philips North America and a member of the Philips North America Leadership Team and has served as Global Marketing Leader for Diagnostic X-Ray in Shanghai, China, in addition to various leadership positions in Europe. Venker is a Dutch citizen and holds a Master of Science degree in Applied Physics from the University of Groningen and an Executive MBA degree from the Rotterdam School of Management. Reported Earnings • Nov 08
Third quarter 2024 earnings released: kr0.51 loss per share (vs kr0.001 profit in 3Q 2023) Third quarter 2024 results: kr0.51 loss per share (down from kr0.001 profit in 3Q 2023). Revenue: kr57.2m (down 10% from 3Q 2023). Net loss: kr13.1m (down kr13.1m from profit in 3Q 2023). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings. New Risk • Jul 24
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.2% average weekly change). Market cap is less than US$100m (€74.3m market cap, or US$80.6m). Reported Earnings • Jul 24
Second quarter 2024 earnings released: EPS: kr0.67 (vs kr0.064 in 2Q 2023) Second quarter 2024 results: EPS: kr0.67 (up from kr0.064 in 2Q 2023). Revenue: kr101.7m (up 37% from 2Q 2023). Net income: kr17.2m (up kr15.7m from 2Q 2023). Profit margin: 17% (up from 2.1% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings. Reported Earnings • Apr 29
Full year 2023 earnings released: kr0.11 loss per share (vs kr1.22 loss in FY 2022) Full year 2023 results: kr0.11 loss per share (improved from kr1.22 loss in FY 2022). Revenue: kr275.1m (up 25% from FY 2022). Net loss: kr2.82m (loss narrowed 91% from FY 2022). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings. Duyuru • Apr 26
Mentice AB (publ) to Report Fiscal Year 2023 Final Results on Apr 24, 2024 Mentice AB (publ) announced that they will report fiscal year 2023 final results on Apr 24, 2024 Reported Earnings • Feb 16
Full year 2023 earnings released: kr0.11 loss per share (vs kr1.22 loss in FY 2022) Full year 2023 results: kr0.11 loss per share (improved from kr1.22 loss in FY 2022). Revenue: kr275.1m (up 25% from FY 2022). Net loss: kr2.82m (loss narrowed 91% from FY 2022). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings. New Risk • Feb 07
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: €92.3m (US$99.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (€92.3m market cap, or US$99.3m). New Risk • Jan 18
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company. Duyuru • Jan 06
Mentice Receives FDA 510(K) Clearance for Ankyras Mentice announced that the clinical decision support application ANKYRAS has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). The approval of product by the FDA demonstrates the safety and effectiveness of Ankyras and confirms commitment to providing innovative and high-quality healthcare solutions. The software is designed to assist interventional neuroradiologists in selecting the most suitable flow diverter before interventional treatment of intracranial aneurysms. Ankyras offers an intuitive and precise solution for clinical treatment planning, leading to more accurate prediction than traditional methods. In the United States, it is estimated that 6.7 million individuals have an unruptured brain aneurysm, meaning that 1 out of every 50 people may be affected. Shockingly, every year, approximately 30,000 people experience a rupture in their brain aneurysm. Unfortunately, this rupture is fatal in nearly 50% of cases. Of those who survive, about 66% suffer some permanent neurological deficit. Ankyras is a platform that provides users with various functionalities to investigate device and treatment options in greater detail. It offers unique morphological assessment metrics that provide customers with a comprehensive and interactive analysis of all artery segments, ensuring they are better equipped to handle real-life challenges. The platform has technology supported by a strong IP portfolio that enables users to evaluate final device length, local expansion and porosity, and precisely align the centerline to create accurate simulations for specific devices. Moving forward, Mentice plans to continue improving the Ankyras solution by incorporating advanced functionalities and more treatment modalities, as well as integrating it with other Mentice solutions, especially the recently acquired Biomodex line of biorealistic haptic simulators. To stay up-to-date with the latest Ankyras advancements and its role in device development and treatment strategies for Intracranial Aneurysm Foundation. Duyuru • Dec 13
Mentice AB (publ) (OM:MNTC) agreed to acquire All substantial assets of Biomodex from SIMARATO SAS for €0.2 million. Mentice AB (publ) (OM:MNTC) agreed to acquire All substantial assets of Biomodex from SIMARATO SAS for €0.2 million on December 11, 2023. Recent Insider Transactions • Dec 06
Director recently bought €71k worth of stock On the 1st of December, Lawrence Howell bought around 20k shares on-market at roughly €3.53 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth €2.0m. Insiders have collectively bought €2.0m more in shares than they have sold in the last 12 months. Duyuru • Nov 23
Mentice (publ) Appoints Ulrika Drotz Voksepp as New Chief Financial Officer, Effective January 2, 2024 Mentice AB (publ) appointed Ulrika Drotz Voksepp as CFO, effective January 2, 2024. Ulrikas has previously held several positions where she has demonstrated her ability to establish operational and financial structures to support the business needs of a growing operation. Notably, Ulrika has held Chief Financial Officer positions with Maurten a food tech enterprise; Egain Group a provider of SaaS solutions for energy optimization; Smarteye- a company that specializes in eye- tracking for the automotive industry; and KVD Kvarndammen an e-commerce marketplace for vehicle transactions as both CFO and CEO. During the transition period, Mentice's interim CFO, Henrik Hang, will assist and support Ulrika, who will formally take over the role of CFO on January 2nd. Henrik will continue to support the company's financial activities during the month of January before officially leaving the company on January 31st. The transition period is crucial to ensure a smooth transition and maintain operational andfinancial stability. Duyuru • Oct 31
Mentice AB (Publ) Announces Board Appointments Mentice AB (publ) announced the following persons have been appointed to the company's nomination committee for the Annual General Meeting 2024: Lawrence D Howell, appointed by Karin Howell, Sophie Hagstromer, appointed by Bure Equity; Thomas Ehlin, appointed by Fjarde AP-Fonden; Magnus Nilsson, Chairman of the Board from December 30, 2022; Magnus Nilsson, convener of the first meeting of the Nomination Committee. Reported Earnings • Oct 30
Third quarter 2023 earnings released Third quarter 2023 results: Revenue: kr63.3m (up 19% from 3Q 2022). Net income: kr16.0k (up kr7.76m from 3Q 2022). Profit margin: 0% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has fallen by 31% per year, which means it is performing significantly worse than earnings. Duyuru • Oct 28
Mentice AB (publ), Annual General Meeting, May 23, 2024 Mentice AB (publ), Annual General Meeting, May 23, 2024. Duyuru • Sep 09
Mentice AB (Publ) Appoints of Jonatan Sjöström to Its Executive Management Group as Chief Operating Officer, Effective from September 14, 2023 Mentice AB (publ) announced the appointment of Jonatan Sjöström to its Executive Management Group as Chief Operating Officer (COO). As part of this new role, Jonatan will assume responsibility for overseeing the company's operational functions, including technology, production, procurement, and information technology, to ensure that Mentice maintains its ambition to deliver exceptional solutions to its global clientele while optimizing digital processes. Jonatan has a wealth of experience in business development, strategy, and technology implementation, having previously served as Head of Strategy and a management team member at Volvo Group Connected Solutions. Additionally, as a seasoned management consultant, he has worked on numerous high-profile projects for several organizations in various sectors, such as automotive, retail, energy, and consumer goods. Jonatan will formally join Mentice on September 14, 2023. New Risk • Aug 13
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: €86.7m (US$94.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Market cap is less than US$100m (€86.7m market cap, or US$94.9m). Duyuru • Jul 22
Mentice AB (publ) Announces Chief Financial Officer Changes Mentice AB (publ) appointed Henrik Hang as interim CFO, effective July 21, 2023. He will succeed Gunilla Andersson, whose departure was announced in May, and has held the position since September 2021. Gunilla will support Henrik during the handover period to ensure a sufficient transition and officially leave the company August 22, 2023. Reported Earnings • Jul 20
Second quarter 2023 earnings released: EPS: kr0.06 (vs kr0.72 loss in 2Q 2022) Second quarter 2023 results: EPS: kr0.06 (up from kr0.72 loss in 2Q 2022). Revenue: kr76.9m (up 60% from 2Q 2022). Net income: kr1.47m (up kr19.1m from 2Q 2022). Profit margin: 1.9% (up from net loss in 2Q 2022). The move to profitability was driven by higher revenue. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has fallen by 17% per year whereas the company’s share price has fallen by 18% per year. Board Change • Jun 02
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 2 highly experienced directors. Independent Chairman of the Board Magnus Nilsson was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Duyuru • May 30
Mentice AB (publ) Announces Resignation of Gunilla Andersson as Chief Financial Officer Mentice AB (publ) announced that its CFO, Gunilla Andersson, has decided to leave Mentice. Gunilla will formally leave the Company at the end of August 2023 and be replaced by an interim CFO until a new CFO has been appointed. Reported Earnings • Apr 09
Full year 2022 earnings released: kr1.22 loss per share (vs kr1.18 loss in FY 2021) Full year 2022 results: kr1.22 loss per share (further deteriorated from kr1.18 loss in FY 2021). Revenue: kr219.4m (up 19% from FY 2021). Net loss: kr30.7m (loss widened 5.0% from FY 2021). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 9.3% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings. Reported Earnings • Feb 05
Full year 2022 earnings released: kr1.22 loss per share (vs kr1.18 loss in FY 2021) Full year 2022 results: kr1.22 loss per share (further deteriorated from kr1.18 loss in FY 2021). Revenue: kr218.0m (up 18% from FY 2021). Net loss: kr30.7m (loss widened 5.0% from FY 2021). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has fallen by 24% per year whereas the company’s share price has fallen by 20% per year. Reported Earnings • Oct 30
Third quarter 2022 earnings released: kr0.30 loss per share (vs kr0.29 loss in 3Q 2021) Third quarter 2022 results: kr0.30 loss per share (further deteriorated from kr0.29 loss in 3Q 2021). Revenue: kr51.1m (up 32% from 3Q 2021). Net loss: kr7.75m (loss widened 7.1% from 3Q 2021). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 27% per year, which means it has not declined as severely as earnings. Reported Earnings • Jul 22
Second quarter 2022 earnings released: kr0.71 loss per share (vs kr0.22 loss in 2Q 2021) Second quarter 2022 results: kr0.71 loss per share (down from kr0.22 loss in 2Q 2021). Revenue: kr45.1m (down 2.7% from 2Q 2021). Net loss: kr17.6m (loss widened 229% from 2Q 2021). Over the next year, revenue is forecast to grow 41%, compared to a 16% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings. Duyuru • Jul 21
Mentice AB (publ) to Report Q4, 2022 Results on Feb 09, 2023 Mentice AB (publ) announced that they will report Q4, 2022 results on Feb 09, 2023 Duyuru • Jul 02
Mentice AB (publ) (OM:MNTC) completed the acquisition of All assets of the Ankyras software suite from Galgo Medical SL. Mentice AB (publ) (OM:MNTC) agreed to acquire All assets of the Ankyras software suite from Galgo Medical SL for €2.775 million on June 9, 2022. Consideration amount of €1.80 million with a possible additional purchase amount of €0.975 million, and with a total purchase consideration amounting to approximately €2.775 million to be paid in cash. The completion of the Acquisition is expected to occur in June 2022 and is conditioned upon customary terms and completed external financing. The agreement and the completion of the said agreement is conditioned upon Mentice financing the transaction, which is planned to be performed through a directed new share issue.
Mentice AB (publ) (OM:MNTC) completed the acquisition of All assets of the Ankyras software suite from Galgo Medical SL on June 30, 2022. Reported Earnings • Apr 29
First quarter 2022 earnings released: kr0.30 loss per share (vs kr0.50 loss in 1Q 2021) First quarter 2022 results: kr0.30 loss per share (up from kr0.50 loss in 1Q 2021). Revenue: kr54.7m (up 69% from 1Q 2021). Net loss: kr7.43m (loss narrowed 40% from 1Q 2021). Over the next year, revenue is forecast to grow 27%, compared to a 26% growth forecast for the industry in Germany. Board Change • Apr 29
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Director Magnus Nilsson was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Duyuru • Apr 28
Mentice AB (publ) Announces Change of Chairman of Board, Effective December 30, 2022 Mentice AB (publ) at its annual general meeting held on April 27, 2022, announced that Lawrence D. Howell was re-elected as chairman of the board up and until December 30, 2022 and Magnus Nilsson was elected as chairman of the board from December 30, 2022 up and until the annual general meeting of 2023. Board Change • Apr 07
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Director Magnus Nilsson was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Duyuru • Feb 15
Mentice Appoints Jan Grund Pedersen as New Vice President of Strategic Alliances & Business Development Mentice announced the appointment of Jan Grund Pedersen as the Vice President for Strategic Alliances & Business Development. Jan possesses over twenty-five years of extensive experience within Virtual Reality (VR) simulation and is one of the founding members of Mentice. Throughout Jan's career, he has spearheaded many innovative areas that have changed the way Physicians see Medical simulation. Duyuru • Feb 12
Mentice AB (publ) to Report Fiscal Year 2021 Results on Apr 06, 2022 Mentice AB (publ) announced that they will report fiscal year 2021 results on Apr 06, 2022 Reported Earnings • Feb 04
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Full year 2021 results: kr1.18 loss per share (down from kr0.54 loss in FY 2020). Revenue: kr190.2m (up 38% from FY 2020). Net loss: kr29.2m (loss widened 123% from FY 2020). Revenue exceeded analyst estimates by 2.9%. Over the next year, revenue is forecast to grow 42%, compared to a 48% growth forecast for the industry in Germany. Reported Earnings • Oct 29
Third quarter 2021 earnings released: kr0.29 loss per share (vs kr0.014 loss in 3Q 2020) The company reported a soft third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: kr39.7m (up 19% from 3Q 2020). Net loss: kr7.23m (loss widened kr6.89m from 3Q 2020). Board Change • Sep 14
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Gosta Johannesson was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Sep 09
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Gosta Johannesson was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Sep 07
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Gosta Johannesson was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Executive Departure • Sep 07
Chief Financial Officer Elisabet Lund has left the company On the 1st of September, Elisabet Lund's tenure as Chief Financial Officer ended. As of June 2021, Elisabet still personally held only 5.00k shares (€41k worth at the time). Elisabet is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 5.17 years. Reported Earnings • Jul 27
Second quarter 2021 earnings released: kr0.22 loss per share (vs kr0.46 loss in 2Q 2020) The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: kr46.4m (up 91% from 2Q 2020). Net loss: kr5.36m (loss narrowed 52% from 2Q 2020). Board Change • Jul 27
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Gosta Johannesson was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Jul 23
Second quarter 2021 earnings released: kr0.22 loss per share (vs kr0.46 loss in 2Q 2020) The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: kr46.4m (up 91% from 2Q 2020). Net loss: kr5.36m (loss narrowed 52% from 2Q 2020). Reported Earnings • May 01
First quarter 2021 earnings released: kr0.50 loss per share (vs kr0.21 loss in 1Q 2020) The company reported a poor first quarter result with increased losses and weaker control over costs, although revenues were flat. First quarter 2021 results: Revenue: kr33.5m (flat on 1Q 2020). Net loss: kr12.4m (loss widened 149% from 1Q 2020). Is New 90 Day High Low • Feb 06
New 90-day low: €7.52 The company is down 3.0% from its price of €7.77 on 06 November 2020. The German market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €7.74 per share. Reported Earnings • Feb 06
Full year 2020 earnings released: kr0.54 loss per share (vs kr1.05 loss in FY 2019) The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: kr150.9m (up 1.0% from FY 2019). Net loss: kr13.1m (loss narrowed 36% from FY 2019). Analyst Estimate Surprise Post Earnings • Feb 06
Revenue misses expectations Revenue missed analyst estimates by 14%. Over the next year, revenue is forecast to grow 33%, compared to a 19% growth forecast for the Healthcare Services industry in Germany. Duyuru • Jan 14
Mentice Announces Executive Appointments Mentice appointed Martin Harris as Global Vice President of Marketing. Mr. Harris has many years' experience with Mentice and was previously responsible for Strategic Alliance partnerships, which he will continue to manage as part of Marketing. The new marketing organization will also assume responsibility for Sales Operations and Sales Training to support the continued regional expansion of the Mentice sales force. Kjell Asserlind has been appointed as Vice President and General Manager for the EMEA region. Mr. Asserlind previously held the position of Global VP for Healthcare Systems Sales. Thanos Karras, appointed General Manager for the Americas region in July 2020 will continue in this role with an expanded organization and additional responsibility. For the APAC region, Mentice has externally recruited a Vice President and General Manager to be separately announced. In addition, Ben Speich has been appointed to run the Vascular Simulations business, acquired in October 2020. Mr. Speich will serve as General Manager for this business unit and be responsible for its operations. He was previously responsible for Global Support at Mentice. Reported Earnings • Nov 13
Third quarter 2020 earnings released: kr0.01 loss per share The company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: kr35.8m (up 22% from 3Q 2019). Net loss: kr340.0k (loss narrowed 96% from 3Q 2019). Analyst Estimate Surprise Post Earnings • Nov 13
Revenue misses expectations Revenue missed analyst estimates by 1.8%. Over the next year, revenue is forecast to grow 28%, compared to a 242% growth forecast for the Healthcare Services industry in Germany. Is New 90 Day High Low • Oct 29
New 90-day low: €7.00 The company is down 1.0% from its price of €7.10 on 30 July 2020. The German market is down 5.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Healthcare Services industry, which is up 2.0% over the same period. Duyuru • Oct 10
Mentice AB (publ) (OM:MNTC) entered into agreement to acquire substantially all assets of EQIP, Inc. for $0.25 million. Mentice AB (publ) (OM:MNTC) entered into agreement to acquire substantially all assets of EQIP, Inc. for $0.25 million on October 8, 2020. The purchase price amounts to $0.18 million with a possible additional purchase price of maximum $0.07 million. Payment will be made in cash of about $0.09 million and remaining $0.09 million through by an off-set issuance of new shares in Mentice corresponding to the agreed purchase price which will be issued based on the authorization for the board to resolve on new issuance of shares given at the annual shareholders’ meeting on May 27 2020. Purchase price will be paid with a directed new shares issue in MenticeAB and cash payment. Mentice intends to initially add the myIRlog™ services to its Mentice Live™ cloud offering and over time to roll out corresponding logbook services to all specialties within the endovascular and interventional fields. The transaction is subject to customary closing conditions and completion of the acquisition is expected to take place in the beginning of October 2020. Duyuru • Oct 02
Mentice AB (publ) (OM:MNTC) signed a definitive agreement to acquire Substantial All Assets of Vascular Simulations LLC for $6 million. Mentice AB (publ) (OM:MNTC) signed a definitive agreement to acquire Substantial All Assets of Vascular Simulations LLC for $6 million on October 1, 2020. Under the terms of agreement, payment will be made through by an off-set issuance of new shares in Mentice corresponding to the agreed purchase price of $5.6 million and with a possible additional purchase price of maximum $0.4 million. Shares which will be issued based on the authorization for the Board to resolve on new issuance of shares given at the annual shareholders’ meeting on May 27, 2020. The transaction includes all the Vascular Simulations assets and significant staff where initially Vascular Simulations will be run as a separate business unit during the integration in the rest of the Mentice enterprise. Vascular Simulation had $2.2 million in revenue for the year ending December 31, 2019 and for the first 9 months 2020, Vascular Simulation had $1 million in revenue. The transaction is subject to customary closing conditions and is expected to close in the beginning of October 2020. Duyuru • Aug 16
Mentice AB (publ) to Report Q2, 2020 Results on Aug 13, 2020 Mentice AB (publ) announced that they will report Q2, 2020 results at 9:30 AM, Central European Standard Time on Aug 13, 2020 Duyuru • Aug 14
Mentice AB (publ) to Report Q3, 2020 Results on Nov 12, 2020 Mentice AB (publ) announced that they will report Q3, 2020 results at 8:30 AM, Central European Standard Time on Nov 12, 2020 
